Effectiveness of adjuvant chemotherapy for resected NSCLC

被引：4

作者：

Stuschke, Martin ^{[1
]}

Poettgen, Christoph ^{[1
]}

机构：

[1] Univ Duisburg Essen, Dept Radiotherapy, D-45122 Essen, Germany

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2010年 / 7卷 / 11期

关键词：

CELL LUNG-CANCER; RADIOTHERAPY; GUIDELINE; THERAPY; SOCIETY; TRIAL; IIIA;

D O I：

10.1038/nrclinonc.2010.165

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Two meta-analyses of the Non Small Cell Lung Cancer Meta-analyses Collaborative Group (NSCLC MACG) on the effects of adjuvant chemotherapy on early stage NSCLC after complete or curative resection have demonstrated that adjuvant cisplatin-based regimens are a valid and recommendable option following curative surgery. We discuss these results in the light of current interdisciplinary guidelines and existing meta-analyses of randomized clinical trials.

引用

页码：613 / 614

页数：2

共 50 条

[41] Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
Wu, Yi-Long
John, Thomas
Grohe, Christian
Majem, Margarita
Goldman, Jonathan W.
Kim, Sang-We
Kato, Terufumi
Laktionov, Konstantin
Vu, Huu Vinh
Wang, Zhijie
Lu, Shun
Lee, Kye Young
Akewanlop, Charuwan
Yu, Chong-Jen
de Marinis, Filippo
Bonanno, Laura
Domine, Manuel
Shepherd, Frances A.
Zeng, Lingmin
Atasoy, Ajlan
Herbst, Roy S.
Tsuboi, Masahiro
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (03) : 423 - 433
[42] Adjuvant chemotherapy dose delivery for completely resected NSCLC in a regional cancer centre: analysis of outcomes by age and comorbidity
Wood, S.
Li, R.
Beesley, S.
Brown, J.
Cominos, M.
Hall, J.
Sevitt, T.
Shah, R.
Taylor, H.
Burcombe, R.
[J]. LUNG CANCER, 2015, 87 : S26 - S26
[43] The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study
Eralp, Y.
Ak, N.
Yilmazbayhan, D.
Ozkan, B.
Ferhatoglu, F.
Demirkazik, A.
Sak, S. Dizbay
Dilege, S.
Tanju, S.
Toker, A.
Bulutay, P.
Firat, P.
Mandel, N. Molinas
Kilickap, S.
Onder, S.
Dikmen, E.
Alan, O.
Yumuk, P. F.
Bozkurtlar, E.
Lacin, T.
Ozturk, A.
Kocaturk, C.
Karapinar, K.
Urer, N.
Uluc, B. Oyan
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S892 - S893
[44] ADJUVANT CISPLATINUM-DOCETAXEL CHEMOTHERAPY IN STAGE IB-II RESECTED NSCLC PATIENTS: THE TOLEDO TRIAL
Bosquee, L.
Germonprez, P.
Aerts, J.
Peters, F.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S52 - S53
[45] BRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy: SCAT Trial
Massuti Sureda, B.
Sanchez Torres, J. M.
Cobo Dols, M.
Moran Bueno, M. T.
Gonzalez-Larriba, J. L.
Barneto Aranda, I. C.
De Castro Carpeno, J.
Iglesias, L.
Munoz, M. A.
Lopez Vivanco, G.
Casado, M. D. Isla
Lopez, R.
de las Penas Bataller, R.
Rodriguez Abreu, D.
Artal-Cortes, A.
Esteban, E.
Provencio, M.
Pereira, E.
Sanchez-Paya, J.
Rosell, R.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[46] Comparative effectiveness of adjuvant chemotherapy in surgically resected non-small cell lung cancer.
Ali, Sara Mariam
Wisnivesky, Juan P.
Smith, Cardinale B.
Mhango, Grace
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[47] Cisplatin vs carboplatin in adjuvant NSCLC chemotherapy
Haridass, A.
Eswar, C. V.
Wong, H.
[J]. LUNG CANCER, 2015, 87 : S25 - S26
[48] Cost-effectiveness of adjuvant chemotherapy with uracil–tegafur for curatively resected stage III rectal cancer
A Hisashige
S Yoshida
S Kodaira
[J]. British Journal of Cancer, 2008, 99 : 1232 - 1238
[49] Adjuvant cisplatin chemotherapy should not be given in NSCLC
Thatcher, N
[J]. LUNG CANCER, 2004, 45 : S25 - S26
[50] Actual Situation of Adjuvant Chemotherapy for NSCLC in Japan
Nakajima, Ryu
Inoue, Hidetoshi
Kimura, Michitaka
Tsukioka, Takuma
Takahama, Makoto
Yamamoto, Ryoji
[J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S563 - S564

← 1 2 3 4 5 →